JP2017505329A - 炎症性障害の治療のための新規な塩及びその医薬組成物 - Google Patents

炎症性障害の治療のための新規な塩及びその医薬組成物 Download PDF

Info

Publication number
JP2017505329A
JP2017505329A JP2016550633A JP2016550633A JP2017505329A JP 2017505329 A JP2017505329 A JP 2017505329A JP 2016550633 A JP2016550633 A JP 2016550633A JP 2016550633 A JP2016550633 A JP 2016550633A JP 2017505329 A JP2017505329 A JP 2017505329A
Authority
JP
Japan
Prior art keywords
salt
compound
disease
hcl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016550633A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505329A5 (OSRAM
Inventor
ルク サボウラウルト ニコラス
ルク サボウラウルト ニコラス
デ ファベリ カルラ
デ ファベリ カルラ
シェイクフ アフマド
シェイクフ アフマド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of JP2017505329A publication Critical patent/JP2017505329A/ja
Publication of JP2017505329A5 publication Critical patent/JP2017505329A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L63/00—Network architectures or network communication protocols for network security
    • H04L63/04—Network architectures or network communication protocols for network security for providing a confidential data exchange among entities communicating through data packet networks
    • H04L63/0428—Network architectures or network communication protocols for network security for providing a confidential data exchange among entities communicating through data packet networks wherein the data content is protected, e.g. by encrypting or encapsulating the payload
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L63/00—Network architectures or network communication protocols for network security
    • H04L63/06—Network architectures or network communication protocols for network security for supporting key management in a packet data network
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L63/00—Network architectures or network communication protocols for network security
    • H04L63/08—Network architectures or network communication protocols for network security for authentication of entities
    • H04L63/0861—Network architectures or network communication protocols for network security for authentication of entities using biometrical features, e.g. fingerprint, retina-scan
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L63/00—Network architectures or network communication protocols for network security
    • H04L63/20—Network architectures or network communication protocols for network security for managing network security; network security policies in general
    • H04L63/205—Network architectures or network communication protocols for network security for managing network security; network security policies in general involving negotiation or determination of the one or more network security mechanisms to be used, e.g. by negotiation between the client and the server or between peers or by selection according to the capabilities of the entities involved
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L67/00—Network arrangements or protocols for supporting network services or applications
    • H04L67/01—Protocols
    • H04L67/10—Protocols in which an application is distributed across nodes in the network
    • H04L67/104—Peer-to-peer [P2P] networks
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L67/00—Network arrangements or protocols for supporting network services or applications
    • H04L67/50—Network services
    • H04L67/51—Discovery or management thereof, e.g. service location protocol [SLP] or web services
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/80—Services using short range communication, e.g. near-field communication [NFC], radio-frequency identification [RFID] or low energy communication
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W8/00—Network data management
    • H04W8/22—Processing or transfer of terminal data, e.g. status or physical capabilities
    • H04W8/24—Transfer of terminal data
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W92/00—Interfaces specially adapted for wireless communication networks
    • H04W92/16—Interfaces between hierarchically similar devices
    • H04W92/18—Interfaces between hierarchically similar devices between terminal devices

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Computer Security & Cryptography (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Computing Systems (AREA)
  • General Engineering & Computer Science (AREA)
  • Computer Hardware Design (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Databases & Information Systems (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2016550633A 2014-02-07 2015-02-04 炎症性障害の治療のための新規な塩及びその医薬組成物 Pending JP2017505329A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1402071.3 2014-02-07
GBGB1402071.3A GB201402071D0 (en) 2014-02-07 2014-02-07 Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
PCT/EP2015/052242 WO2015117981A1 (en) 2014-02-07 2015-02-04 Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020011555A Division JP2020097595A (ja) 2014-02-07 2020-01-28 炎症性障害の治療のための新規な塩及びその医薬組成物

Publications (2)

Publication Number Publication Date
JP2017505329A true JP2017505329A (ja) 2017-02-16
JP2017505329A5 JP2017505329A5 (OSRAM) 2018-03-15

Family

ID=50390572

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016550633A Pending JP2017505329A (ja) 2014-02-07 2015-02-04 炎症性障害の治療のための新規な塩及びその医薬組成物
JP2020011555A Pending JP2020097595A (ja) 2014-02-07 2020-01-28 炎症性障害の治療のための新規な塩及びその医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020011555A Pending JP2020097595A (ja) 2014-02-07 2020-01-28 炎症性障害の治療のための新規な塩及びその医薬組成物

Country Status (28)

Country Link
US (7) US9382247B2 (OSRAM)
EP (2) EP3102575B1 (OSRAM)
JP (2) JP2017505329A (OSRAM)
KR (1) KR102478614B1 (OSRAM)
CN (2) CN111499630A (OSRAM)
AR (1) AR099307A1 (OSRAM)
AU (4) AU2015215045B2 (OSRAM)
CA (1) CA2938219C (OSRAM)
CY (1) CY1124349T1 (OSRAM)
DK (1) DK3102575T3 (OSRAM)
EA (2) EA201990330A1 (OSRAM)
ES (1) ES2853375T3 (OSRAM)
GB (1) GB201402071D0 (OSRAM)
HR (1) HRP20210194T1 (OSRAM)
HU (1) HUE053309T2 (OSRAM)
IL (1) IL246833B (OSRAM)
LT (1) LT3102575T (OSRAM)
MX (2) MX376000B (OSRAM)
NZ (1) NZ722603A (OSRAM)
PL (1) PL3102575T3 (OSRAM)
PT (1) PT3102575T (OSRAM)
RS (1) RS61450B1 (OSRAM)
SG (2) SG11201606433PA (OSRAM)
SI (1) SI3102575T1 (OSRAM)
SM (1) SMT202100060T1 (OSRAM)
TW (2) TWI792593B (OSRAM)
UY (1) UY35984A (OSRAM)
WO (1) WO2015117981A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020510057A (ja) * 2017-03-14 2020-04-02 ギリアード サイエンシーズ， インコーポレイテッド Ｊａｋ阻害剤を含む医薬組成物

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201402070D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2016165953A1 (en) * 2015-04-13 2016-10-20 Galapagos Nv Methods for the treatment of inflammatory disorders
WO2016165952A1 (en) * 2015-04-13 2016-10-20 Galapagos Nv Methods for the treatment of cardiovascular disorders
AU2016278040B2 (en) 2015-06-16 2019-07-04 Nanophagix LLC Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
CN105198879B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物c晶型及其制备方法
CN105198878B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物f晶型及其制备方法
CN105111207B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物d晶型及其制备方法
CN105111206B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物e晶型及其制备方法
CN105198877B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物g晶型及其制备方法
CN105198880B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物a晶型及其制备方法
CN105218539B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物b晶型及其制备方法
CN105198876B (zh) * 2015-09-18 2017-09-29 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物h晶型及其制备方法
WO2017106568A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a bromodomain inhibitor for treating cancer
US20170174788A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
WO2017106564A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
CN105669669A (zh) * 2016-03-04 2016-06-15 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物的a晶型、b晶型、d晶型、g晶型和m晶型及其制备方法
WO2017162139A1 (zh) 2016-03-21 2017-09-28 苏州晶云药物科技有限公司 用于治疗或预防jak相关疾病药物的盐酸盐晶型及其制备方法
WO2018024236A1 (zh) * 2016-08-03 2018-02-08 苏州科睿思制药有限公司 一种jak1选择性抑制剂的新晶型及其制备方法和用途
CA3043396A1 (en) 2016-11-10 2018-05-17 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
GB201702603D0 (en) 2017-02-17 2017-04-05 Galápagos Nv Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201808575D0 (en) 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits
US10815227B2 (en) 2018-08-27 2020-10-27 Cadila Healthcare Limited Processes for the preparation of filgotinib
US11882438B2 (en) * 2018-10-29 2024-01-23 Zorday IP, LLC Network-enabled electronic cigarette
WO2020177705A1 (zh) * 2019-03-05 2020-09-10 苏州科睿思制药有限公司 Filgotinib的马来酸盐晶型CSI及其制备方法和用途
AU2020251400B2 (en) * 2019-03-30 2025-02-06 Unichem Laboratories Limited Novel process for the preparation of filgotinib and intermediates thereof
WO2021044327A1 (en) * 2019-09-03 2021-03-11 Dr. Reddy's Laboratories Limited Solid forms of filgotinib maleate and processes thereof
CN114075188A (zh) * 2020-08-11 2022-02-22 南京柯菲平盛辉制药有限公司 芳香杂环酰胺类化合物及其制备方法和医药用途
CN116963752A (zh) * 2020-12-09 2023-10-27 赛瓦图斯有限公司 用于关节的炎性紊乱的组合疗法
CN113773322B (zh) * 2021-11-10 2022-02-11 奥锐特药业(天津)有限公司 一种Filgotinib的制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011036895A1 (ja) * 2009-09-25 2011-03-31 杏林製薬株式会社 マレイン酸塩およびその結晶
JP2011529032A (ja) * 2008-07-25 2011-12-01 ガラパゴス・ナムローゼ・フェンノートシャップ 変性及び炎症性疾患の治療に有用な新規化合物
JP2012530766A (ja) * 2009-06-26 2012-12-06 ガラパゴス・ナムローゼ・フェンノートシャップ ＪＡＫ阻害剤としての５−フェニル−［１，２，４］トリアゾロ［１，５−ａ］ピリジン−２−イルカルボキサミド
JP2013049632A (ja) * 2011-08-30 2013-03-14 Kowa Co ベンゾチアジン化合物のモノマレイン酸塩を有効成分とするアレルギー疾患の予防及び／又は治療剤
JP2013518828A (ja) * 2010-02-04 2013-05-23 チャンスー ヘンルイ メディシン カンパニー リミテッド ピロロ窒素複素環誘導体の薬学的に許容される塩、その調製法、および医学的使用
WO2013189771A1 (en) * 2012-06-22 2013-12-27 Galapagos Nv Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2549632B2 (ja) * 1986-08-20 1996-10-30 三井石油化学工業株式会社 オレフインの重合方法
ES2228451T3 (es) 1999-01-29 2005-04-16 Chugai Seiyaku Kabushiki Kaisha Promotores de condrogenesis y derivados de indolin-2-ona.
WO2002087620A1 (en) 2001-04-27 2002-11-07 Chugai Seiyaku Kabushiki Kaisha Chondrogenesis promoters
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
WO2004039816A1 (ja) * 2002-10-29 2004-05-13 Shionogi & Co., Ltd. セフェム化合物の無機酸塩の結晶
ES2264795T3 (es) 2003-02-14 2007-01-16 Pfizer Products Inc. Triazolo-piridinas como compuestos antiinflamatorios.
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
EP2360474B1 (en) 2004-06-21 2013-07-24 Galapagos N.V. Methods and means for treatment of osteoarthritis
CA2577478A1 (en) 2004-08-18 2006-02-23 Pharmacia & Upjohn Company Llc Triazolopyridine compounds
WO2006038116A2 (en) 2004-10-07 2006-04-13 Warner-Lambert Company Llc Triazolopyridine derivatives as antibacterial agents
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
WO2008025821A1 (en) 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
PE20090370A1 (es) 2007-06-05 2009-04-30 Takeda Pharmaceutical Derivados de heterociclo fusionado como inhibidores de quinasa
MX2010000716A (es) 2007-07-18 2010-03-26 Novartis Ag Compuestos de heteroarilo biciclicos y su uso como inhibidores de cinasa.
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
CN101878212A (zh) 2007-08-31 2010-11-03 默克雪兰诺有限公司 三唑并吡啶化合物及其作为ask抑制剂的用途
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
BRPI0909945A2 (pt) 2008-06-20 2015-07-28 Genentech Inc "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
EP2305673A4 (en) 2008-07-31 2011-11-02 Daiichi Sankyo Co Ltd CRYSTAL OF A THIAZOLIDINE CONNECTION AND METHOD FOR THE PRODUCTION THEREOF
KR20120044966A (ko) 2009-06-05 2012-05-08 세파론, 인코포레이티드 1,2,4-트리아졸로〔1,5ａ〕 피리딘 유도체의 제조 및 용도
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
SA112330992B1 (ar) 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
WO2016165953A1 (en) 2015-04-13 2016-10-20 Galapagos Nv Methods for the treatment of inflammatory disorders
WO2016165952A1 (en) 2015-04-13 2016-10-20 Galapagos Nv Methods for the treatment of cardiovascular disorders
WO2017106564A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
JOP20180018A1 (ar) 2017-03-14 2019-01-30 Gilead Sciences Inc تركيبات صيدلية تتضمن مثبط jak
GB201808575D0 (en) 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529032A (ja) * 2008-07-25 2011-12-01 ガラパゴス・ナムローゼ・フェンノートシャップ 変性及び炎症性疾患の治療に有用な新規化合物
JP2012530766A (ja) * 2009-06-26 2012-12-06 ガラパゴス・ナムローゼ・フェンノートシャップ ＪＡＫ阻害剤としての５−フェニル−［１，２，４］トリアゾロ［１，５−ａ］ピリジン−２−イルカルボキサミド
WO2011036895A1 (ja) * 2009-09-25 2011-03-31 杏林製薬株式会社 マレイン酸塩およびその結晶
JP2013518828A (ja) * 2010-02-04 2013-05-23 チャンスー ヘンルイ メディシン カンパニー リミテッド ピロロ窒素複素環誘導体の薬学的に許容される塩、その調製法、および医学的使用
JP2013049632A (ja) * 2011-08-30 2013-03-14 Kowa Co ベンゾチアジン化合物のモノマレイン酸塩を有効成分とするアレルギー疾患の予防及び／又は治療剤
WO2013189771A1 (en) * 2012-06-22 2013-12-27 Galapagos Nv Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
C.G.WERMUTH編, 最新創薬化学, vol. 下巻, JPN6014029314, 1999, pages 347 - 65, ISSN: 0004122876 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020510057A (ja) * 2017-03-14 2020-04-02 ギリアード サイエンシーズ， インコーポレイテッド Ｊａｋ阻害剤を含む医薬組成物
US12502394B2 (en) 2017-03-14 2025-12-23 Alfasigma S.P.A. Pharmaceutical compositions comprising a JAK inhibitor

Also Published As

Publication number Publication date
US20160376269A1 (en) 2016-12-29
CY1124349T1 (el) 2022-07-22
US20210269435A1 (en) 2021-09-02
AU2019202441B2 (en) 2020-08-06
AU2020260391A1 (en) 2020-11-19
AU2022235624A1 (en) 2022-10-20
TW201613915A (en) 2016-04-16
MX2020003368A (es) 2020-07-29
CN105960407A (zh) 2016-09-21
CA2938219A1 (en) 2015-08-13
RS61450B1 (sr) 2021-03-31
MX395415B (es) 2025-03-19
AU2019202441A1 (en) 2019-05-02
PL3102575T3 (pl) 2021-07-26
CA2938219C (en) 2023-01-24
IL246833A0 (en) 2016-08-31
EP3102575A1 (en) 2016-12-14
AU2020260391B2 (en) 2022-07-28
CN111499630A (zh) 2020-08-07
GB201402071D0 (en) 2014-03-26
HRP20210194T1 (hr) 2021-03-19
IL246833B (en) 2022-07-01
EP3842432A1 (en) 2021-06-30
US20200244651A1 (en) 2020-07-30
MX376000B (es) 2025-03-07
UY35984A (es) 2015-09-30
AR099307A1 (es) 2016-07-13
TW202229274A (zh) 2022-08-01
TWI767878B (zh) 2022-06-21
NZ722603A (en) 2019-07-26
EP3102575B1 (en) 2021-01-13
EA201691584A1 (ru) 2017-01-30
US10708263B2 (en) 2020-07-07
AU2015215045A1 (en) 2016-08-11
SG11201606433PA (en) 2016-09-29
US10919890B2 (en) 2021-02-16
TWI792593B (zh) 2023-02-11
JP2020097595A (ja) 2020-06-25
EA032596B1 (ru) 2019-06-28
US20150225398A1 (en) 2015-08-13
US12234235B2 (en) 2025-02-25
MX2016010068A (es) 2016-11-15
KR20160110518A (ko) 2016-09-21
SI3102575T1 (sl) 2021-04-30
US9382247B2 (en) 2016-07-05
LT3102575T (lt) 2021-04-26
ES2853375T3 (es) 2021-09-15
SG10202013187PA (en) 2021-02-25
AU2015215045B2 (en) 2019-01-24
PT3102575T (pt) 2021-02-04
US20230406857A1 (en) 2023-12-21
SMT202100060T1 (it) 2021-03-15
US20180007043A1 (en) 2018-01-04
US11667633B2 (en) 2023-06-06
DK3102575T3 (da) 2021-02-08
US20250289816A1 (en) 2025-09-18
AU2022235624B2 (en) 2023-11-23
KR102478614B1 (ko) 2022-12-16
EA201990330A1 (ru) 2020-01-31
HUE053309T2 (hu) 2021-06-28
WO2015117981A1 (en) 2015-08-13

Similar Documents

Publication Publication Date Title
US12234235B2 (en) Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JP6633531B2 (ja) 炎症性障害の治療のための医薬組成物
JP5486084B2 (ja) 変性疾患及び炎症性疾患の治療に有用な新規化合物
JP5591925B2 (ja) ＪＡＫ阻害剤としての５−フェニル−［１，２，４］トリアゾロ［１，５−ａ］ピリジン−２−イルカルボキサミド
JP2018048185A (ja) 炎症の治療に使用するためのアミノトリアゾロピリジン及びその医薬組成物
WO2017133423A1 (zh) 一种取代的吡啶酰胺类化合物及其应用
EA041895B1 (ru) Новые соли и их фармацевтические композиции для лечения воспалительных заболеваний
HK1231859A1 (en) Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
HK1231859B (en) Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181009

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190404

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191001

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200128

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20200212

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200212

C27A Decision to dismiss

Free format text: JAPANESE INTERMEDIATE CODE: C2711

Effective date: 20200331

C032 Notice prior to dismissal

Free format text: JAPANESE INTERMEDIATE CODE: C032

Effective date: 20200526

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20200526